Claire Potter

1.1K posts

Claire Potter banner
Claire Potter

Claire Potter

@ce_potter

Wellcome/HRB Fellow @ICATprogramme PhD student @CPH_QUB @QUB_ARF Psychiatry SpR @_NIMDTA @Fulbright_Eire Student 22-23 to @umisr Stress & cognitive ageing 🧠

Belfast, Northern Ireland Entrou em Mart 2017
1.2K Seguindo600 Seguidores
Claire Potter
Claire Potter@ce_potter·
Good luck @CathalMcCrory1! Brilliant collaborative project between @NICOLA_QUB @CPH_QUB, @tilda_tcd and @hrsisr on a novel DNAm based measure of Physiological age 🧬
Cathal McCrory@CathalMcCrory1

Looking forward to presenting our new epigenetic clock work @tilda_tcd @hrsisr @ce_potter at the Centre for Ageing Resilience in a Changing Environment (CARICE) conference in Kings College London. Thanks @DrClaireSteves for the invitation

Castlereagh, Northern Ireland 🇬🇧 English
0
0
1
231
Claire Potter retweetou
Cathal McCrory
Cathal McCrory@CathalMcCrory1·
Looking forward to presenting our new epigenetic clock work @tilda_tcd @hrsisr @ce_potter at the Centre for Ageing Resilience in a Changing Environment (CARICE) conference in Kings College London. Thanks @DrClaireSteves for the invitation
Cathal McCrory tweet media
English
0
6
14
1K
Claire Potter retweetou
Michael Okun
Michael Okun@MichaelOkun·
The randomized trial results are in for the GLP-1 drug Exenatide for Parkinson's disease. Spoiler: NO symptomatic or disease modifying effect. Tom @foltynie @DavidStandaert and I interviewed in the @nytimes @ginakolata on the latest paper just published in @TheLancet by Tom and his colleagues. Key Points: - 'Rigorous' study randomly assigned Parkinson’s folks to take exenatide (a relative of Ozempic). - 194 folks enrolled in the UK. - "No benefit or slowing of the course of Parkinson's after 96 weeks." - "No effect on patient symptoms, no effect on brain scans, no subgroup that showed any benefit. No matter how the researchers sliced the data the results were the same." My take: “This is a sobering moment. This is a really well done study, and it came up empty-handed.” Animal studies and small human studies previously suggested benefit. Another recent smaller study of a similar drug, lixisenatide, in the @NEJM was positive. “Researchers started digging into claims databases...and asked if patients who had taken GLP-1s might be less likely to get Parkinson’s or, if they had it, would have a disease that progressed more slowly...the results were promising." "They looked at epidemiological studies. They found that people with diabetes who took GLP-1s were less likely to have Parkinson’s." When the first study came out Gina quoted me as saying we were “nibbling at the edges of disease modification.” We were however all humbled and this reminds us how important it is to do the science, and not to rush to market or judgement. Dave commented that “he wouldn’t do another study like this unless you learn what is the target...what is the biochemistry you are trying to change in the brain? How do these drugs work, anyway?” Good science means replication. Good science protects the public and in the case of GLP-1s, there can be associated weight loss and loss of muscle mass, and that is something we probably want to avoid in Parkinson's. Ab uno disce omnes – from this one example we learn (all the rest). Let's stay humble, but keep learning and advancing the science for the benefit of those w/ Parkinson's and beyond. thelancet.com/journals/lance… NYTimes article: nytimes.com/2025/02/04/hea… #Parkinsons #GLP1 #ozempic #diabetes
Michael Okun tweet media
English
4
31
106
14.3K
Claire Potter retweetou
Derek Tracy
Derek Tracy@Derektracy1·
A privilege to listen to Sir Michael Marmot talk on inequality in the UK. Some very stark data, but a message of hope for change if the social and political will is there. @rcpsychNI @drjulespsych
Derek Tracy tweet media
English
1
11
47
2.7K
Claire Potter retweetou
Age NI
Age NI@Age_NI·
Five main themes came out of conversations during focus groups: 1. Getting around 2. Access to health and social care 3. Activities for healthy ageing 4. Public spaces 5. Loneliness and isolation #LetsChangeHowWeAge @ce_potter @okaneniamh
Age NI tweet media
English
2
3
11
408
Claire Potter retweetou
SPACE QUB
SPACE QUB@spacequb·
How can two people have the same genetic build up, but face different health issues as we age? 🧬 It's like baking - we might have the same ingredients, but the way we prepare them will impact the outcome 🎂 How we live our lives impacts how we age @ce_potter
GIF
English
0
1
3
364
Claire Potter retweetou
Age NI
Age NI@Age_NI·
Researcher @ce_potter gives context for the @spacequb piece of work. “Studies have shown that rural ageing can be associated with less age acceleration. There are measurable differences between health behaviors and health outcomes based on whether a participant lives in an urban or rural area.”
Age NI tweet media
English
0
3
6
295
Claire Potter
Claire Potter@ce_potter·
An interactive workshop, I will be presenting results from @NICOLA_QUB & we will hear about the brilliant work done in collaboration with people living in these areas and @spacequb, @Age_NI and @PaulHogarthCo on the issues important to them, challenges and potential solutions
Castlereagh, Northern Ireland 🇬🇧 English
1
0
2
83
Claire Potter retweetou
Dr Cassandra Wannan
Dr Cassandra Wannan@cassie_wannan·
My amazing friend and colleague, Dr Isabelle Scott, has just published this fantastic viewpoint in @JAMAPsych, discussing the limitations of current psychiatric nosologies for the development of clinical prediction models: tinyurl.com/2vj7jmsh
English
2
23
62
6.8K